

Special Issue

Biomarkers in Colorectal Cancer

Message from the Guest Editors

Dear Colleagues Colorectal cancer is the third cancer, both in terms of incidence and mortality in Western countries. Currently, molecular biomarkers play an important role in the detection and treatment of colorectal cancer patients. Molecular biomarkers are useful in recognizing colorectal cancer susceptibility or in the screening and diagnosis of early stages of the disease. The presence or absence of specific prognostic and predictive tumour biomarkers lead to a more rational selection of pharmacological treatments for colorectal cancer with consequent improvements in outcome. Molecular biomarkers predictive of drug toxicity are also available and help clinicians in the choice of the safest drug treatment for each patient. In this Special Issue, the current knowledge, as well as the future perspectives on the role of tumour biomarkers in colorectal cancer screening, diagnosis, treatment and follow-up, will be discussed.

Guest Editors

Prof. Dr. Enrico Mini


Department of Health Sciences, Università degli Studi di Firenze, Florence, Italy

Dr. Stefania Nobili

Department of Neurosciences, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy

Deadline for manuscript submissions

closed (31 October 2018)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/13778

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).